EMA overview regarding the authorisation and safety monitoring of veterinary medicines

 Published: 24 Feb 2022 | Last Updated: 24 Feb 2022 17:24

EMA has published an overview of its key recommendations of 2021 regarding the authorisation and safety monitoring of veterinary medicines.

In 2021, EMA recommended 12 medicines for marketing authorisation. Of these, seven had a new active substance. Five are vaccines, including four new biotechnological vaccines.

A selection of these recommendations can be found in the veterinary medicines highlights document published today.

You have received this mail because you have registered in the EMA stakeholders database and subscribed to receive this kind of information. However, if you no longer wish to receive such communications from us, please send an email to StakeholdersDB@ema.europa.eu to unsubscribe.

We would be grateful if you could disseminate this email to anyone else who might be interested in this information.

With kind regards,

Nathalie Macle

Public and Stakeholders Engagement Department

Stakeholders and Communication Division

 

European Medicines Agency

Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The NetherlandsStakeholdersDB@ema.europa.eu / www.ema.europa.eu